Empagliflozin
- Generic Name
- Empagliflozin
- Brand Names
- Glyxambi, Jardiance, Synjardy, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27ClO7
- CAS Number
- 864070-44-0
- Unique Ingredient Identifier
- HDC1R2M35U
- Background
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...
- Indication
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- Monotherapy
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 16
- Registration Number
- NCT05757791
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
- Conditions
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05681273
- Locations
- 🇨🇳
Zhongshan hospital, Shanghai, China
Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
- Conditions
- Interventions
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 40
- Registration Number
- NCT05669742
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
- Conditions
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 75
- Registration Number
- NCT05614115
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT05610956
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 50
- Registration Number
- NCT05510115
- Locations
- 🇺🇸
University of Coloardo Anschutz Medical Campus, Aurora, Colorado, United States
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30400
- Registration Number
- NCT05465317
- Locations
- 🇺🇸
Duke Clinical Research Institute, Durham, North Carolina, United States
Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity
- Conditions
- Interventions
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT05444153
Use of Empagliflozin to Treat Prediabetes
- Conditions
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Oregon State University
- Target Recruit Count
- 40
- Registration Number
- NCT05426525
- Locations
- 🇺🇸
Oregon State University, Corvallis, Oregon, United States
Impact of SGLT2 on Glucosuria in HNF1A-MODY
- Conditions
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 21
- Registration Number
- NCT05417646
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Herlev, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.